NEWS・COLUMN
We send the latest information from SMC Laboratories.
Today, September 21th, is World Alzheimer’s Day!
We recently mentioned World Alzheimer's Month, including World Alzheimer's Day (Previous article), and today we would like to share SMC's thoughts on the development of a medicine for the treatment of Alzheimer's disease. There are currently five FDA-approved drugs for Alzheimer's disease (Donepezil, Rivastigmine, Galantamine, Memantine, and Aducanumab). These treatments can be divided into…
The importance of the NAFLD activity score and the STAM™ model’s clinical relevance
In this issue, we would like to introduce the NAFLD activity score (NAS), which is one of the main endpoints used in the development of drug candidates for NASH, and the role it plays in our proprietary STAM™ model. But, first, what is NAS and how does it relate to the study of NASH?…
Introducing our Idiopathic Pulmonary Fibrosis (IPF) mouse model
The outbreak of COVID-19 causes a lot of complications and long-term harm to the patient, especially severe pulmonary fibrosis. We offer the Idiopathic Pulmonary Fibrosis (IPF) mouse model as a potential model for the development of therapeutics for lung fibrosis, and many of our customers have used this model through our introduction of its usefulness….
September is World Alzheimer’s Month!
In recognition of September 21st being World Alzheimer’s Day, why don’t we deepen our understanding of Alzheimer's disease? In 1994, the “Alzheimer's Disease International” (ADI), in collaboration with the World Health Organization (WHO), established September 21st as “World Alzheimer's Day” to raise awareness for people who suffer from dementia. In addition to this, September…
SMC attend The Biotechgate Digital Partnering!
We are pleased to announce that SMC Laboratories will be virtually attending the Biotechgate Digital Partnering from August 29th to September 2nd. We would love to have the opportunity to meet with you virtually and introduce ourselves and our preclinical models, so please join us! If you would like to discuss specific collaboration opportunities,…
SMC attend The 8th Taiwan-Japan Pharmaceutical Seminar/Business Matching!
We are pleased to announce that SMC Laboratories will be virtually attending the 8th Taiwan-Japan Pharmaceutical Seminar/Business Matching on September 2nd. So, you can conduct web meeting using Teams. If you are attending the event and are interested in our services or STAM™ mice, please feel free to contact us. Even if you do…
A study using liver samples from the STAM™ model published in PLOS ONE.
SMC is proud to announce that Institut de Recherches Servier (FRA) has published the results of their study using our STAM™ model liver samples in PLOS ONE. Title ”Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression“ In this paper, the authors compared the extent to which C-Proteinase…
SMC announces Presentation of New Data at the International Congress of Endocrinology 2022 (ICE2022).
Today, we are pleased to announce the acceptance of our abstract on our NASH-hepatocellular carcinoma (HCC) model at the International Congress of Endocrinology 2022 (ICE2022) 【Online】, which is to be held on August 25th and 28th. Our presentation will be entitled “RNA-seq Analysis of Liver from NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet”. …
July 28th is World Hepatitis Day!
In recognition of July 28th being World Hepatitis Day, we here at SMC thought it might be a good idea to help everyone around the globe have a deeper understanding of hepatitis, so please read on if you would like to learn more. In 2010, the World Health Organization (WHO) designated July 28th as…
Drug Efficacy Study in the STAM™ Model Published in Translational Oncology
SMC is proud to announce that Kurume University (JPN) has published the results of their study using our STAM™ model in Translational Oncology. Title “Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments“ In this study, the authors evaluated the anti-tumor effect of combining sorafenib…
SMC attend BIO One-on-One Partnering™ in Bio Asia Taiwan!
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One PartneringTM in Bio Asia Taiwan from July 27th to 31th. So, you can conduct web meeting using Zoom. If you are attending the event and are interested in our services or STAMTM mice, please feel free to contact us. …
SMC announces Presentation of New Data at the 29th conference of The Japanese Society for the Research of Hepatic Cells.
Today, we are pleased to announce the acceptance of our abstract on our NASH-hepatocellular carcinoma (HCC) model at the 29th convention of The Japanese Society for the Research of Hepatic Cells, which is to be held on August 25th and 26th. This will be the first time that our company has presented at an event…